SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED

Andere talen SciClone Pharmaceuticals (Holdings) Limited

Aandelen

6600

KYG4271B1023

Vertraagde tijd Hong Kong S.E. Andere beurzen 05:58:14 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
18 ^HKD	+0,11%		0,00%	+29,31%

01/04	SciClone Pharmaceuticals boekt 31% meer winst in 2023	MT
28/03	Sciclone Pharmaceuticals (Holdings) Limited kondigt wijzigingen in de leiding aan	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31	18/04
SciClone Pharmaceuticals Logs 31% Increase in 2023 Profit	01/04
Sciclone Pharmaceuticals Limited Announces Executive Changes	28/03
SciClone Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
SciClone Completes Patient Enrollment for Urinary Tract Infection Drug's Phase 3 Trial; Shares Rise 3%	01/02
SciClone Pharmaceuticals Limited Announces Phase III Clinical Trial of Vaborem® Completed Subject Enrollment in China	31/01
Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer	07/11
SciClone Signs Licensing Deal with Menarini for Breast Cancer Drug; Shares Rise 3%	07/11
SciClone Pharmaceuticals Limited and Menarini Establish License and Collaboration Agreement for Orserdu in China	06/11
SciClone Pharmaceuticals' Profit Jumps 18.4% in H1	18-08-23
SciClone Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023	17-08-23
SciClone Pharmaceuticals Doses First Patient in Phase 3 Study for Urinary Tract Infection Injection	05-07-23
SciClone Pharmaceuticals Limited Announces First Subject Dosed in Phase III Clinical Trial of Vaborem in China	05-07-23
SciClone Commercially Launches Neuroblastoma Treatment in China	03-07-23
SciClone Pharmaceuticals Limited Announces Commercial Launch of DANYELZA in China	02-07-23
SciClone Pharmaceuticals Limited commences an Equity Buyback Plan for 61,829,507 shares, representing 10% of its issued share capital, under the authorization approved on May 25, 2023.	06-06-23
SciClone Pharmaceuticals Limited Approves a Final Dividend for the Year Ended December 31, 2022	25-05-23
Sciclone Pharmaceuticals Limited Elects Ms. Pan Rongrong as an Executive Director of the Company	25-05-23
SciClone Pharmaceuticals Limited's Equity Buyback announced on May 20, 2022, has expired.	25-05-23
Sciclone Pharmaceuticals Limited Announces Retirement of SHI Cen as Non-Executive Director	22-05-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen SciClone Pharmaceuticals (Holdings) Limited

Aandelen

6600

KYG4271B1023

Andere talen

Filters